Is ZIM Laboratories (NSE:ZIMLAB) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We note that ZIM Laboratories Limited (NSE:ZIMLAB) does have debt on its balance sheet. But is this debt a concern to shareholders?This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. What Risk Does Debt Bring? Debt assists a business until the business has trouble paying it off, either with new capital or with free cash flow. If things get really bad, the lenders can take control of the business. However, a more common (but still painful) scenario is that it has to raise new equity capital at a low price, thus permanently diluting shareholders. Having said that, the most common situation is where a company manages its debt reasonably well - and to its own advantage. The first step when considering a company's debt levels is to consider its cash and debt together. How Much Debt Does ZIM Laboratories Carry? As you can see below, at the end of September 2025, ZIM Laboratories had ₹1.17b of debt, up from ₹973.5m a year ago. Click the image for more detail. On the flip side, it has ₹46.3m in cash leading to net debt of about ₹1.13b. NSEI:ZIMLAB Debt to Equity History January 16th 2026 How Healthy Is ZIM Laboratories' Balance Sheet? We can see from the most recent balance sheet that ZIM Laboratories had liabilities of ₹1.60b falling due within a year, and liabilities of ₹585.5m due beyond that. Offsetting these obligations, it had cash of ₹46.3m as well as receivables valued at ₹1.02b due within 12 months. So its liabilities total ₹1.12b more than the combination of its cash and short-term receivables. This deficit isn't so bad because ZIM Laboratories is worth ₹3.69b, and thus could probably raise enough capital to shore up its balance sheet, if the need arose. However, it is still worthwhile taking a close look at its ability to pay off debt. View our latest analysis for ZIM Laboratories We measure a company's debt load relative to its earnings power by looking at its net debt divided by its earnings before interest, tax, depreciation, and amortization (EBITDA) and by calculating how easily its earnings before interest and tax (EBIT) cover its interest expense (interest cover). The advantage of this approach is that we take into account both the absolute quantum of debt (with net debt to EBITDA) and the actual interest expenses associated with that debt (with its interest cover ratio). While we wouldn't worry about ZIM Laboratories's net debt to EBITDA ratio of 3.5, we think its super-low interest cover of 1.7 times is a sign of high leverage. It seems clear that the cost of borrowing money is negatively impacting returns for shareholders, of late. Worse, ZIM Laboratories's EBIT was down 37% over the last year. If earnings keep going like that over the long term, it has a snowball's chance in hell of paying off that debt. The balance sheet is clearly the area to focus on when you are analysing debt. But you can't view debt in total isolation; since ZIM Laboratories will need earnings to service that debt. So if you're keen to discover more about its earnings, it might be worth checking out this graph of its long term earnings trend. Finally, a company can only pay off debt with cold hard cash, not accounting profits. So we clearly need to look at whether that EBIT is leading to corresponding free cash flow. During the last three years, ZIM Laboratories burned a lot of cash. While that may be a result of expenditure for growth, it does make the debt far more risky. Our View On the face of it, ZIM Laboratories's conversion of EBIT to free cash flow left us tentative about the stock, and its EBIT growth rate was no more enticing than the one empty restaurant on the busiest night of the year. Having said that, its ability to handle its total liabilities isn't such a worry. Overall, it seems to us that ZIM Laboratories's balance sheet is really quite a risk to the business. For this reason we're pretty cautious about the stock, and we think shareholders should keep a close eye on its liquidity. When analysing debt levels, the balance sheet is the obvious place to start. But ultimately, every company can contain risks that exist outside of the balance sheet. We've identified 4 warning signs with ZIM Laboratories (at least 1 which is potentially serious) , and understanding them should be part of your investment process. At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.